CRONOS GROUP INC (CRON) Fundamental Analysis & Valuation
NASDAQ:CRON • CA22717L1013
Current stock price
2.53 USD
+0.01 (+0.4%)
At close:
2.52 USD
-0.01 (-0.4%)
After Hours:
This CRON fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.
1. CRON Profitability Analysis
1.1 Basic Checks
- In the past year CRON has reported negative net income.
- CRON had a positive operating cash flow in the past year.
- CRON had negative earnings in 4 of the past 5 years.
- In multiple years CRON reported negative operating cash flow during the last 5 years.
1.2 Ratios
- With a decent Return On Assets value of -0.79%, CRON is doing good in the industry, outperforming 78.13% of the companies in the same industry.
- With an excellent Return On Equity value of -0.86%, CRON belongs to the best of the industry, outperforming 80.21% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -0.79% | ||
| ROE | -0.86% | ||
| ROIC | N/A |
ROA(3y)-1.25%
ROA(5y)-9.2%
ROE(3y)-1.24%
ROE(5y)-9.62%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
- CRON's Gross Margin of 42.81% is fine compared to the rest of the industry. CRON outperforms 63.02% of its industry peers.
- In the last couple of years the Gross Margin of CRON has grown nicely.
- The Profit Margin and Operating Margin are not available for CRON so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 42.81% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y34%
GM growth 5YN/A
2. CRON Health Analysis
2.1 Basic Checks
- CRON does not have a ROIC to compare to the WACC, probably because it is not profitable.
- Compared to 1 year ago, CRON has less shares outstanding
- CRON has more shares outstanding than it did 5 years ago.
- There is no outstanding debt for CRON. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
2.2 Solvency
- An Altman-Z score of 7.09 indicates that CRON is not in any danger for bankruptcy at the moment.
- Looking at the Altman-Z score, with a value of 7.09, CRON belongs to the top of the industry, outperforming 81.77% of the companies in the same industry.
- There is no outstanding debt for CRON. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 7.09 |
ROIC/WACCN/A
WACC8.18%
2.3 Liquidity
- CRON has a Current Ratio of 19.59. This indicates that CRON is financially healthy and has no problem in meeting its short term obligations.
- CRON has a Current ratio of 19.59. This is amongst the best in the industry. CRON outperforms 91.15% of its industry peers.
- A Quick Ratio of 18.62 indicates that CRON has no problem at all paying its short term obligations.
- CRON's Quick ratio of 18.62 is amongst the best of the industry. CRON outperforms 91.15% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 19.59 | ||
| Quick Ratio | 18.62 |
3. CRON Growth Analysis
3.1 Past
- CRON shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -104.00%.
- Looking at the last year, CRON shows a very strong growth in Revenue. The Revenue has grown by 24.63%.
- Measured over the past years, CRON shows a very strong growth in Revenue. The Revenue has been growing by 25.70% on average per year.
EPS 1Y (TTM)-104%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-103.64%
Revenue 1Y (TTM)24.63%
Revenue growth 3Y19.11%
Revenue growth 5Y25.7%
Sales Q2Q%46.96%
3.2 Future
- CRON is expected to show a very negative growth in Earnings Per Share. In the coming years, the EPS will decrease by -72.39% yearly.
- Based on estimates for the next years, CRON will show a small growth in Revenue. The Revenue will grow by 0.19% on average per year.
EPS Next Y1714.91%
EPS Next 2Y359.62%
EPS Next 3Y210.9%
EPS Next 5Y-72.39%
Revenue Next Year31.91%
Revenue Next 2Y23.45%
Revenue Next 3Y14.53%
Revenue Next 5Y0.19%
3.3 Evolution
- The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
4. CRON Valuation Analysis
4.1 Price/Earnings Ratio
- Based on the Price/Forward Earnings ratio of 39.17, the valuation of CRON can be described as expensive.
- Based on the Price/Forward Earnings ratio, CRON is valued a bit cheaper than 70.83% of the companies in the same industry.
- Compared to an average S&P500 Price/Forward Earnings ratio of 23.69, CRON is valued quite expensively.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | 39.17 |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
- The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
- CRON's earnings are expected to grow with 210.90% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y359.62%
EPS Next 3Y210.9%
5. CRON Dividend Analysis
5.1 Amount
- No dividends for CRON!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
CRON Fundamentals: All Metrics, Ratios and Statistics
2.53
+0.01 (+0.4%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)02-26 2026-02-26/bmo
Earnings (Next)05-06 2026-05-06
Inst Owners15.08%
Inst Owner Change0%
Ins Owners6.34%
Ins Owner Change4.54%
Market Cap961.80M
Revenue(TTM)146.59M
Net Income(TTM)-9.45M
Analysts82.22
Price Target3.44 (35.97%)
Short Float %2.14%
Short Ratio3.34
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)1
Avg Revenue beat(2)4.13%
Min Revenue beat(2)-4.49%
Max Revenue beat(2)12.75%
Revenue beat(4)1
Avg Revenue beat(4)1.94%
Min Revenue beat(4)-4.49%
Max Revenue beat(4)12.75%
Revenue beat(8)4
Avg Revenue beat(8)1.09%
Revenue beat(12)5
Avg Revenue beat(12)-0.47%
Revenue beat(16)6
Avg Revenue beat(16)-2.81%
PT rev (1m)0%
PT rev (3m)-7.7%
EPS NQ rev (1m)-100%
EPS NQ rev (3m)-100%
EPS NY rev (1m)0%
EPS NY rev (3m)-9.53%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-10.78%
Revenue NY rev (1m)-4.4%
Revenue NY rev (3m)2.38%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | 39.17 | ||
| P/S | 6.56 | ||
| P/FCF | N/A | ||
| P/OCF | 37.18 | ||
| P/B | 0.88 | ||
| P/tB | 0.94 | ||
| EV/EBITDA | N/A |
EPS(TTM)0
EYN/A
EPS(NY)0.06
Fwd EY2.55%
FCF(TTM)0
FCFYN/A
OCF(TTM)0.07
OCFY2.69%
SpS0.39
BVpS2.88
TBVpS2.68
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -0.79% | ||
| ROE | -0.86% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 42.81% | ||
| FCFM | N/A |
ROA(3y)-1.25%
ROA(5y)-9.2%
ROE(3y)-1.24%
ROE(5y)-9.62%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y34%
GM growth 5YN/A
F-Score7
Asset Turnover0.12
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | 183.09% | ||
| Cap/Sales | 17.78% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 19.59 | ||
| Quick Ratio | 18.62 | ||
| Altman-Z | 7.09 |
F-Score7
WACC8.18%
ROIC/WACCN/A
Cap/Depr(3y)118.29%
Cap/Depr(5y)94.57%
Cap/Sales(3y)10.61%
Cap/Sales(5y)10.82%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-104%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-103.64%
EPS Next Y1714.91%
EPS Next 2Y359.62%
EPS Next 3Y210.9%
EPS Next 5Y-72.39%
Revenue 1Y (TTM)24.63%
Revenue growth 3Y19.11%
Revenue growth 5Y25.7%
Sales Q2Q%46.96%
Revenue Next Year31.91%
Revenue Next 2Y23.45%
Revenue Next 3Y14.53%
Revenue Next 5Y0.19%
EBIT growth 1Y75.45%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year219.41%
EBIT Next 3Y74.89%
EBIT Next 5Y-8.2%
FCF growth 1Y-103.34%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y37.27%
OCF growth 3YN/A
OCF growth 5YN/A
CRONOS GROUP INC / CRON Fundamental Analysis FAQ
What is the fundamental rating for CRON stock?
ChartMill assigns a fundamental rating of 5 / 10 to CRON.
What is the valuation status of CRONOS GROUP INC (CRON) stock?
ChartMill assigns a valuation rating of 2 / 10 to CRONOS GROUP INC (CRON). This can be considered as Overvalued.
Can you provide the profitability details for CRONOS GROUP INC?
CRONOS GROUP INC (CRON) has a profitability rating of 3 / 10.
What is the financial health of CRONOS GROUP INC (CRON) stock?
The financial health rating of CRONOS GROUP INC (CRON) is 9 / 10.